-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On 7 January, Gan Li Pharmaceuticals announced that it had received a registration approval from the Indonesian Drug Administration for the registration of mendon insulin API (batch number: RG.01.01.32.322.12.20.01214/H).
winter insulin raw materials can be used for filling the production of gate winter insulin injection, gate winter insulin injection is a quick-acting insulin similar products, also known as meal insulin, after injection can be quickly absorbed, can be injected immediately before or after meals, to bring convenience to patients.
Compared with soluble human insulin, menwine insulin after injection faster, shorter duration of action, more in line with the human body after meal physiological insulin secretion mode, close to the meal injection, application is more convenient, can significantly improve blood sugar after meals, so menwine insulin injection has become a particularly important insulin in diabetes treatment.
Indonesia, with a population of 262 million in Southeast Asia, is the world's fourth most populous country with a per capita GDP of US$3,894 (international exchange rate in 2018), and has 10.7 million diabetes cases among adults aged 20-79, ranking seventh in the world (IDF2019).
currently, in Indonesia, the main suppliers of mendon insulin injections are No.
's Mendon insulin product NovoRapid?, will have global sales of approximately DKK 18.06 billion in 2019 (NovoRapid?
as of September 30, 2020, the company has invested approximately 103 million yuan in its mendong insulin research and development program.